Bin Huang
Directeur Général chez Taizhou Huan Sheng Investment Management Co., Ltd.
Fortune : 25 M $ au 31/05/2024
Postes actifs de Bin Huang
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Collected Mind Ltd.
 Collected Mind Ltd. Financial ConglomeratesFinance Part of 3SBio, Inc., Collected Mind Ltd. functions as an investment holding There is no available country named vg company. | Directeur/Membre du Conseil | 01/08/2006 | - |
| Taizhou Huan Sheng Investment Management Co., Ltd. | Directeur/Membre du Conseil | 01/11/2010 | - |
| Directeur Général | 01/11/2010 | - | |
Shenyang Sunshine Pharmaceuticals Co., Ltd.
 Shenyang Sunshine Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Shenyang Sunshine Pharmaceutical Co., Ltd. engages in the development and production of biological products. It offers recombinant human erythropoietin, interferon alfa 2b, interleukin 2, and thrombopoietin injections. Its business activities include research and development, and manufacture of biochemical reagents, and pharmaceutical project investment advisory services. The company was founded on January 3, 1993 and is headquartered in Shenyang, China. | Directeur/Membre du Conseil | 01/01/1993 | - |
| Corporate Officer/Principal | - | - | |
| Responsable des Ressources Humaines | 01/01/1993 | - |
Historique de carrière de Bin Huang
Anciens postes connus de Bin Huang
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| 3SBIO INC. | Directeur/Membre du Conseil | 01/01/2006 | 25/06/2024 |
| Corporate Officer/Principal | 01/01/1993 | 20/06/2019 | |
Chemokine Therapeutics Corp.
 Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - | - |
Statistiques
Internationale
| Chine | 4 |
| Canada | 2 |
Opérationnelle
| Director/Board Member | 4 |
| Corporate Officer/Principal | 3 |
| Chief Executive Officer | 1 |
Sectorielle
| Health Technology | 4 |
| Finance | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| 3SBIO INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Chemokine Therapeutics Corp.
Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | Health Technology |
Collected Mind Ltd.
Collected Mind Ltd. Financial ConglomeratesFinance Part of 3SBio, Inc., Collected Mind Ltd. functions as an investment holding There is no available country named vg company. | Finance |
Shenyang Sunshine Pharmaceuticals Co., Ltd.
Shenyang Sunshine Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Shenyang Sunshine Pharmaceutical Co., Ltd. engages in the development and production of biological products. It offers recombinant human erythropoietin, interferon alfa 2b, interleukin 2, and thrombopoietin injections. Its business activities include research and development, and manufacture of biochemical reagents, and pharmaceutical project investment advisory services. The company was founded on January 3, 1993 and is headquartered in Shenyang, China. | Health Technology |
